I期子宫恶性肿瘤患者术后基于ctDNA的分子残留病灶检测
该研究分析101例I期子宫内膜癌患者的267份血浆样本,采用肿瘤知情ctDNA检测(Signatera™定制mPCR-NGS)术后监测,中位随访6.8个月。首次和纵向ctDNA阳性患者无复发生存期更差(HR分别为6.2和15.5),复发率分别为58%和52%,而ctDNA阴性患者分别为6%和0%。
要点
- 术后ctDNA阳性与I期子宫内膜癌复发风险升高相关。
- 首次和纵向ctDNA阳性患者无复发生存期更差(HR=6.2和15.5)。
- 调整临床病理风险因素后,可检测ctDNA仍是复发的唯一显著风险因素。
核心结论
- 将ctDNA监测与已知传统风险因素结合,可能有助于识别I期子宫内膜癌中复发风险最高的患者,并可能辅助治疗分层。
研究设计与样本
- 本分析基于真实世界数据,纳入101例I期子宫内膜癌患者,采用肿瘤知情ctDNA检测(Signatera™定制mPCR-NGS)分析267份血浆样本。
- 患者术后接受ctDNA检测监测,中位随访6.8个月(范围0.37-19.1)。
主要发现
- 首次检测ctDNA阳性患者无复发生存期更差(HR=6.2;p=0.0006),复发率为58%,而ctDNA阴性患者为6%。
- 纵向ctDNA阳性患者无复发生存期更差(HR=15.5;p<0.0001),复发率为52%,而ctDNA阴性患者为0%。
- 大多数ctDNA阳性患者为高风险组织学类型或肉瘤,而非低风险和高中间风险(H-IR)子宫内膜癌。
- 高风险组织学类型中ctDNA阳性患者无复发生存期短于ctDNA阴性患者(HR=9.5;p=0.007),也短于低/高中间风险队列中ctDNA阳性患者(HR=0.25;p=0.04)。
- 术后可检测ctDNA对临床结局有高度预后价值,调整组织学风险组、错配修复(MMR)和p53状态等临床病理风险因素后,仍是复发的唯一显著风险因素。
临床怎么用
- 作者认为,将ctDNA监测与已知传统风险因素结合,可能有助于识别I期子宫内膜癌中复发风险最高的患者,并可能辅助治疗分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Among uterine malignancies, endometrial cancer (EC) is the most common cancer of the female reproductive tract. Traditionally, risk stratification in EC is determined by standard clinicopathological risk factors. Although circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker in various malignancies, its clinical validity in EC remains to be established. METHODS: In this analysis of real-world data, 267 plasma samples from 101 patients with stage I EC were analyzed using a tumor-informed ctDNA assay (Signatera™ bespoke mPCR-NGS). Patients were followed post-surgically and monitored with ctDNA testing for a median of 6.8 months (range: 0.37-19.1). RESULTS: Patients who tested ctDNA-positive at both their first time point and longitudinally experienced inferior recurrence-free survival (RFS) (HR = 6.2; p = 0.0006 and HR = 15.5; p < 0.0001, respectively), and showed a recurrence rate of 58% and 52%, vs. 6% and 0%, respectively for the ctDNA-negative patients. Most ctDNA-positive patients had high-risk histologies or sarcoma, versus low-risk and high-intermediate risk (H-IR) EC. Furthermore, patients with high-risk histologies who were ctDNA-positive showed shorter RFS compared to those who tested negative (HR = 9.5; p = 0.007), and those who tested positive in the low/H-IR cohort (HR = 0.25; p = 0.04). Post-surgically, detectable ctDNA was highly prognostic of clinical outcome and remained the only significant risk factor for recurrence when adjusted for clinicopathological risk factors, such as histologic risk group, mismatch repair (MMR), and p53 status. CONCLUSION: Incorporating ctDNA monitoring along with traditional known risk factors may aid in identifying patients with stage I EC who are at highest risk of recurrence, and possibly aid in treatment stratification.
引用
- Recio F, Scalise CB, Loar P, et al. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies. Gynecol Oncol. 2024. PMID: 38262240. doi:10.1016/j.ygyno.2023.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。